Amit Bar-or

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1042805/publications.pdf

Version: 2024-02-01

		8732	7496
214	25,087	75	151
papers	citations	h-index	g-index

227	227	227	20283
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	B-Cell Depletion with Rituximab in Relapsingâ€“Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	13.9	2,107
2	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	13.9	1,324
3	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	13.9	1,322
4	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 2014, 507, 366-370.	13.7	882
5	Multiple sclerosis. Nature Reviews Disease Primers, 2018, 4, 43.	18.1	767
6	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
7	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, The, 2011, 378, 1779-1787.	6.3	636
8	Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. Journal of Immunology, 2007, 178, 6092-6099.	0.4	567
9	B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6â€“producing B cells. Journal of Experimental Medicine, 2012, 209, 1001-1010.	4.2	530
10	Rituximab in relapsingâ€remitting multiple sclerosis: A 72â€week, openâ€label, phase I trial. Annals of Neurology, 2008, 63, 395-400.	2.8	484
11	Abnormal Bâ€cell cytokine responses a trigger of Tâ€cellâ€“mediated disease in MS?. Annals of Neurology, 2010, 67, 452-461.	2.8	428
12	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nature Medicine, 2021, 27, 1990-2001.	15.2	396
13	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	13.9	358
14	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	2.3	356
15	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Medicine, 2007, 13, 211-217.	15.2	342
16	Proinflammatory GM-CSFâ€“producing B cells in multiple sclerosis and B cell depletion therapy. Science Translational Medicine, 2015, 7, 310ra166.	5.8	334
17	Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?. Journal of Immunology, 2004, 172, 3422-3427.	0.4	316
18	Roles of microglia in brain development, tissue maintenance and repair. Brain, 2015, 138, 1138-1159.	3.7	316

#	Article	IF	Citations
19	Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 2003, 126, 2738-2749.	3.7	300
20	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585.	6.3	296
21	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	4.9	292
22	Reassessing B cell contributions in multiple sclerosis. Nature Immunology, 2018, 19, 696-707.	7.0	275
23	Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs, 2014, 74, 659-674.	4.9	274
24	Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1383.	4.9	271
25	Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology, 2020, 95, e1999-e2008.	1.5	269
26	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	4.9	267
27	Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell, 2019, 176, 610-624.e18.	13.5	241
28	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	13.9	237
29	Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment. Journal of Immunology, 2008, 181, 5730-5737.	0.4	233
30	Serial Antiâ€“Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurology, 2020, 77, 82.	4.5	213
31	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	4.9	191
32	Natalizumab effects on immune cell responses in multiple sclerosis. Annals of Neurology, 2006, 59, 748-754.	2.8	190
33	miRâ€155 as a multiple sclerosisâ€“relevant regulator of myeloid cell polarization. Annals of Neurology, 2013, 74, 709-720.	2.8	189
34	Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis. Journal of Immunology, 2004, 172, 7144-7153.	0.4	187
35	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	4.9	184
36	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.4	182

#	Article	IF	Citations
37	Epsteinâ€“Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine, 2020, 26, 296-310.	3.5	178
38	Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. Immunity, 2015, 43, 1160-1173.	6.6	176
39	Determinants of Human B Cell Migration Across Brain Endothelial Cells. Journal of Immunology, 2003, 170, 4497-4505.	0.4	175
40	Microglia and multiple sclerosis. Journal of Neuroscience Research, 2005, 81, 363-373.	1.3	174
41	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	2.1	170
42	Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology, 2018, 90, e1805-e1814.	1.5	165
43	Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial. Archives of Neurology, 2007, 64, 1407.	4.9	159
44	The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. Journal of Clinical Immunology, 2001, 21, 81-92.	2.0	155
45	Biology of Adult Human Microglia in Culture: Comparisons with Peripheral Blood Monocytes and Astrocytes. Journal of Neuropathology and Experimental Neurology, 1992, 51, 538-549.	0.9	153
46	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. Journal of Neuroscience, 2005, 25, 2537-2546.	1.7	150
47	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	4.9	150
48	Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. Journal of Neuroimmunology, 2012, 246, 85-95.	1.1	145
49	P2Y12 expression and function in alternatively activated human microglia. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e80.	3.1	139
50	B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104.	3.1	132
51	MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells. Journal of Immunology, 2016, 196, 3375-3384.	0.4	128
52	Immunological Memory: Contribution of Memory B Cells Expressing Costimulatory Molecules in the Resting State. Journal of Immunology, 2001, 167, 5669-5677.	0.4	126
53	Role of B Cells in Multiple Sclerosis and Related Disorders. Annals of Neurology, 2021, 89, 13-23.	2.8	123
54	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Frontiers in Immunology, 2015, 6, 636.	2.2	120

#	Article	IF	Citations
55	Treatment of multiple sclerosis with Anti-CD20 antibodies. Clinical Immunology, 2012, 142, 31-37.	1.4	118
56	The Immunology of Multiple Sclerosis. Seminars in Neurology, 2008, 28, 029-045.	0.5	117
57	T follicular helper cells in human efferent lymph retain lymphoid characteristics. Journal of Clinical Investigation, 2019, 129, 3185-3200.	3.9	116
58	Coexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells. Journal of Immunology, 2015, 194, 3687-3696.	0.4	115
59	Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. Journal of Immunology, 2017, 198, 691-698.	0.4	112
60	B cells in multiple sclerosis â€" from targeted depletion to immune reconstitution therapies. Nature Reviews Neurology, 2021, 17, 399-414.	4.9	110
61	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	3.1	104
62	Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. Journal of Neuroimmunology, 2005, 158, 213-221.	1.1	102
63	Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurology, The, 2021, 20, 470-483.	4.9	96
64	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. Journal of Neuroimmunology, 2003, 136, 140-148.	1.1	92
65	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Science Translational Medicine, 2019, 11, .	5.8	92
66	COVID-19 and MS disease-modifying therapies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	91
67	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurology, The, 2020, 19, 336-347.	4.9	90
68	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	4.9	89
69	Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia, 2007, 55, 516-526.	2.5	87
70	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	2.7	86
71	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 501-511.	1.4	86
72	B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. Journal of Neuroimmunology, 2017, 309, 88-99.	1.1	85

#	Article	IF	Citations
73	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.5	81
74	A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e105421.	1.1	81
75	Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment. Journal of Neuroimmunology, 2006, 180, 3-8.	1.1	80
76	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4, 93-104.	1.4	80
77	Abnormal Tâ€cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Annals of Neurology, 2008, 63, 98-111.	2.8	77
78	Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. Journal of Clinical Neuroscience, 2011, 18, 997-998.	0.8	77
79	Direct and Indirect Effects of Immune and Central Nervous Systemâ€“Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation. Journal of Immunology, 2015, 194, 761-772.	0.4	75
80	Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. Frontiers in Immunology, 2015, 6, 657.	2.2	73
81	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	1.6	73
82	Dimethyl fumarateâ€“induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e340.	3.1	73
83	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain, 2019, 142, 617-632.	3.7	72
84	Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology, 2020, 16, 56-62.	4.9	71
85	Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nature Medicine, 2000, 6, 211-214.	15.2	69
86	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 626.	2.2	69
87	Effect of dimethyl fumarate on lymphocytes in RRMS. Neurology, 2019, 92, e1724-e1738.	1.5	66
88	TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. Journal of Immunology, 2015, 194, 5761-5774.	0.4	65
89	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386.	1.5	64
90	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsingâ€“remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305.	1.8	62

#	Article	IF	Citations
91	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology, 2014, 83, 2219-2226.	1.5	58
92	The Identity of Human Tissue-Emigrant CD8+ T Cells. Cell, 2020, 183, 1946-1961.e15.	13.5	58
93	Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Multiple Sclerosis Journal, 2018, 24, 632-641.	1.4	57
94	Neurological immunotherapy in the era of COVID-19 â€" looking for consensus in the literature. Nature Reviews Neurology, 2020, 16, 493-505.	4.9	57
95	Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. Journal of Pineal Research, 1991, 10, 141-147.	3.4	54
96	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain, 2017, 140, 1300-1315.	3.7	52
97	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 834.	2.2	51
98	Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. Journal of Neuroimmunology, 2014, 268, 95-98.	1.1	50
99	Cytokineâ€producing B cells: aÂtranslational view on their roles in human and mouse autoimmune diseases. Immunological Reviews, 2016, 269, 130-144.	2.8	50
100	Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology, 2016, 87, S12-9.	1.5	49
101	MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e402.	3.1	49
102	Efficacy of delayedâ€release dimethyl fumarate in relapsingâ€remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2015, 2, 103-118.	1.7	48
103	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Multiple Sclerosis Journal, 2015, 21, 735-748.	1.4	47
104	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 yearsâ€™ follow-up of DEFINE, CONFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091500.	1.5	47
105	A proteome map of axoglial specializations isolated and purified from human central nervous system. Glia, 2010, 58, 1949-1960.	2.5	46
106	B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nature Reviews Immunology, 2008, 8, 486-487.	10.6	45
107	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. Science Translational Medicine, 2019, 11, .	5.8	45
108	Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Reviews Neurology, 2011, 7, 109-122.	4.9	43

#	Article	IF	Citations
109	Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking. PLoS ONE, 2014, 9, e115920.	1.1	43
110	Monophasic demyelination reduces brain growth in children. Neurology, 2017, 88, 1744-1750.	1.5	43
111	A surfaceâ€in gradient of thalamic damage evolves in pediatric multiple sclerosis. Annals of Neurology, 2019, 85, 340-351.	2.8	42
112	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	4.9	41
113	Recovery From Central Nervous System Acute Demyelination in Children. Pediatrics, 2015, 136, e115-e123.	1.0	40
114	Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. Journal of Neuroinflammation, 2018, 15, 114.	3.1	40
115	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e277.	3.1	39
116	Do Myelin-Directed Antibodies Predict Multiple Sclerosis?. New England Journal of Medicine, 2003, 349, 107-109.	13.9	37
117	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	1.4	37
118	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology, 2019, 93, e1778-e1786.	1.5	37
119	Teriflunomide (AubagioÂ®) for the treatment of multiple sclerosis. Experimental Neurology, 2014, 262, 57-65.	2.0	36
120	Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia, 2003, 42, 36-45.	2.5	35
121	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e276.	3.1	35
122	Elevated serum inflammatory markers in post-poliomyelitis syndrome. Journal of the Neurological Sciences, 2008, 271, 80-86.	0.3	34
123	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	1.7	34
124	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	2.8	33
125	Pineal involvement in the diurnal rhythm of nociception in the rat. Life Sciences, 1989, 44, 1067-1075.	2.0	32
126	Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Multiple Sclerosis Journal, 2017, 23, 1225-1232.	1.4	32

#	Article	IF	Citations
127	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	0.5	32
128	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal, 2019, 25, 515-522.	1.4	32
129	Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. Journal of Immunology, 2017, 198, 3245-3254.	0.4	31
130	Myelin regulates immune cell adhesion and motility. Experimental Neurology, 2009, 217, 371-377.	2.0	30
131	Immunology of multiple sclerosis. Neurologic Clinics, 2005, 23, 149-175.	0.8	29
132	BTK inhibition limits B-cellâ€“T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathologica, 2022, 143, 505-521.	3.9	29
133	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal, 2022, 28, 910-924.	1.4	27
134	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	2.8	27
135	Exosome-enriched fractions from MS B cells induce oligodendrocyte death. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e550.	3.1	26
136	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	0.9	26
137	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1033-1043.	0.9	26
138	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs, 2021, 35, 985-997.	2.7	26
139	Long-term safety and efficacy of dimethyl fumarate for up to 13â€‰years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	1.4	26
140	Targeting Progressive Neuroaxonal Injury. CNS Drugs, 2011, 25, 783-799.	2.7	25
141	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	1.4	25
142	Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 466-475.	4.9	25
143	Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. Scientific Reports, 2020, 10, 356.	1.6	24
144	Rasmussen encephalitis and comorbid autoimmune diseases. Neurology, 2014, 83, 1049-1055.	1.5	22

#	Article	IF	Citations
145	Emerging multiple sclerosis disease-modifying therapies. Current Opinion in Neurology, 2009, 22, 226-232.	1.8	21
146	Pediatric-onset multiple sclerosis is associated with reduced parental healthâ€“related quality of life and family functioning. Multiple Sclerosis Journal, 2019, 25, 1661-1672.	1.4	21
147	Manifestations and impact of the COVIDâ€19 pandemic in neuroinflammatory diseases. Annals of Clinical and Translational Neurology, 2021, 8, 918-928.	1.7	21
148	Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	21
149	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 767-775.	1.7	20
150	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	1.4	19
151	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	0.9	19
152	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	1.4	19
153	Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clinical Immunology, 2004, 111, 38-46.	1.4	18
154	EBV and brain matter(s)?. Neurology, 2010, 74, 1092-1095.	1.5	18
155	The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029108.	2.9	17
156	Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies. NeuroImage, 2020, 208, 116442.	2.1	17
157	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurology: Clinical Practice, 2020, 10, 510-519.	0.8	17
158	Laquinimod in multiple sclerosis. Clinical Immunology, 2012, 142, 38-43.	1.4	16
159	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	1.4	16
160	Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive multiple sclerosis. JCI Insight, 2022, 7, .	2.3	16
161	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	1.4	16
162	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	1.4	16

#	Article	IF	Citations
163	Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment. Multiple Sclerosis Journal, 2017, 23, 567-576.	1.4	15
164	Differential transcriptional response profiles in human myeloid cell populations. Clinical Immunology, 2018, 189, 63-74.	1.4	15
165	Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicdaâ^'/â^' and Ungâ^'/â^' Mice. Journal of Immunology, 2018, 201, 1119-1130.	0.4	15
166	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. PLoS ONE, 2019, 14, e0218215.	1.1	15
167	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.5	15
168	Guilty by association: Epsteinâ€“Barr virus in multiple sclerosis. Nature Medicine, 2022, 28, 904-906.	15.2	15
169	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	1.4	12
170	Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. Current Opinion in Neurology, 2022, 35, 319-327.	1.8	12
171	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. Multiple Sclerosis Journal, 2019, 25, 980-986.	1.4	11
172	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	2.4	11
173	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	4.5	11
174	Unraveling B lymphocytes in CNS inflammatory diseases. Neurology, 2020, 95, 733-744.	1.5	10
175	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	1.4	10
176	From bench to MS bedside: Challenges translating biomarker discovery to clinical practice. Journal of Neuroimmunology, 2012, 248, 66-72.	1.1	9
177	Central nervous system inflammation across the age span. Current Opinion in Neurology, 2016, 29, 381-387.	1.8	9
178	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	1.4	9
179	Pathways to cures for multiple sclerosis: A research roadmap. Multiple Sclerosis Journal, 2022, 28, 331-345.	1.4	9
180	Antigen-specific therapies in multiple sclerosis. Expert Opinion on Emerging Drugs, 2009, 14, 551-560.	1.0	8

#	Article	IF	Citations
181	Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis. Journal of Immunology, 2021, 207, 44-54.	0.4	8
182	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Multiple Sclerosis and Related Disorders, 2022, 63, 103829.	0.9	8
183	Factors associated with health care utilization in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101511.	0.9	7
184	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	1.8	7
185	The immunology of multiple sclerosis. , 2011, , 20-34.		6
186	Beta interferons in clinically isolated syndromes: a meta-analysis. Arquivos De Neuro-Psiquiatria, 2008, 66, 8-10.	0.3	5
187	Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow). Scientific Reports, 2020, 10, 14823.	1.6	5
188	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	1.4	5
189	Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery.. Neuropsychology, 2021, 35, 388-398.	1.0	5
190	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e499.	3.1	4
191	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. Multiple Sclerosis and Related Disorders, 2019, 36, 101387.	0.9	4
192	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. Multiple Sclerosis Journal, 2022, 28, 1299-1310.	1.4	4
193	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Frontiers in Neurology, 2022, 13, 828616.	1.1	4
194	Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. Multiple Sclerosis and Related Disorders, 2012, 1, 116-122.	0.9	3
195	A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit. Multiple Sclerosis Journal, 2019, 25, 1170-1177.	1.4	3
196	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	0.5	3
197	Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study). Multiple Sclerosis Journal, 2022, 28, 82-92.	1.4	3
198	Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study. Neurology, 2021, 96, 870-870.	1.5	2

#	Article	IF	Citations
199	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal, 2022, 28, 1819-1824.	1.4	2
200	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	0.9	2
201	<scp>B</scp> cells set trends: Lessons from multiple sclerosis. Clinical and Experimental Neuroimmunology, 2012, 3, 89-108.	0.5	1
202	Sequencing the immunopathologic heterogeneity in multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 873-874.	1.7	1
203	CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Proteinâ€"Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response. Journal of Immunology, 2021, 207, 1513-1521.	0.4	1
204	Editorial: Update on Translational Neuroimmunology - Research of ISNI 2018. Frontiers in Immunology, 2020, 11, 2012.	2.2	1
205	113â€... Benefit-risk of ofatumumab in treatment-naÃ¯ve early relapsing multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A136.2-A136.	0.9	1
206	B-cell-based therapies for multiple sclerosis. , 0, , 483-497.		0
207	Multiple sclerosis meets systems immunology â€" Authors' reply. Lancet Neurology, The, 2021, 20, 888.	4.9	0
208	Evidence of in vivo Immune Modulation with Vitamin D3 and Calcium Supplementation in Multiple Sclerosis. FASEB Journal, 2010, 24, 537.23.	0.2	0
209	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. Child Neuropsychology, 2021, , 1-22.	0.8	0
210	033â€... Ocrelizumab: serum Ig levels and serious infections. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A23.3-A24.	0.9	0
211	043â€... Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.1-A27.	0.9	0
212	045â€... Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.3-A27.	0.9	0
213	116â€... Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A137.2-A137.	0.9	0
214	010â€... Safety and efficacy of long-term dimethyl fumarate treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A16.4-A17.	0.9	0